Tumor mutational burden (TMB), PDL-1 expression, microbiome, hypoxia, IFN-γ, Extracellular matrix, and molecular and cellular characterization within the tumor microenvironment are related to immunotherapy outcomes [152]. This evidence concerns the gene IFNG and neoplasm.